ew45percentblacklrga12.jpg
Edwards Lifesciences Corporation
One Edwards Way · Irvine, CA USA · 92614
Phone: 949.250.2500 · Fax: 949.250.2525
www.edwards.com

FOR IMMEDIATE RELEASE
 
Media Contact:  Sarah Huoh, 949-250-5070
Investor Contact:  David K. Erickson, 949-250-6826
 
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS 
IRVINE, Calif., January 31, 2019 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2018.
Fourth Quarter and Full Year Highlights
Q4 sales grew 10.0%; full year 2018 sales grew 8.4%, underlying1 sales grew 10.0%
Q4 THVT sales grew 14.1%; full year 2018 sales grew 12.8%, underlying sales grew 12.2%
Full year 2018 EPS grew 25%; adjusted EPS grew 24%
Reconfirmed 2019 total company adjusted sales and EPS guidance ranges
Global litigation settlement relating to transcatheter therapies
SAPIEN 3 Ultra approved in Europe and U.S.
“We are pleased to report strong fourth quarter performance that delivered 10 percent sales growth on an underlying basis, consistent with our expectations, driven by our portfolio of innovative technologies. For the full year 2018, we reported 10 percent growth on an underlying basis, also in line with our guidance. Profitability was also strong in 2018, with adjusted EPS growing over 20 percent, even as we continued to invest aggressively in our innovation initiatives and infrastructure,” said Michael A. Mussallem, chairman and CEO. “We are as convinced as ever in the tremendous opportunity to improve patients’ lives by addressing deadly conditions and bringing significant value to the healthcare system.”
Fourth Quarter 2018 Results
Sales for the quarter ended December 31, 2018 were $978 million, or $983 million on an adjusted basis, both up 10 percent over the prior year. Diluted earnings per share for the quarter was $0.03 per share, while adjusted earnings per share grew 25 percent to $1.17.

Transcatheter Heart Valve Therapies (THVT)
For the quarter, the company reported THVT sales of $592 million, a 14 percent growth rate over the fourth quarter last year, or 11 percent on an underlying basis. Estimated global transcatheter aortic valve replacement (TAVR) procedures continued to grow in the mid-teens. Edwards' worldwide sales

1

The following information was filed by Edwards Lifesciences Corp (EW) on Thursday, January 31, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
×

Membership Level change

You have selected the Free membership level.

Get 7 days of FREE access to our online tools for reading 10-Ks and 10-Qs more efficiently:

  • Bullish, Bearish remarks
  • No advertisements
  • Disclosures
  • Wider reading area
  • Email notifications
  • Stock screener

The price for membership is $0.00 now.

Membership expires after 7 Days.


Account Information Already have an account? Log in here

LEAVE THIS BLANK
Your privacy is important to us - We do not rent or sell your personal information
By creating an account, you are agreeing to our Terms and Privacy Policy

Log in with your credentials

or    

Forgot your details?

Create Account